Business Wire Industry News

Friday, March 31, 2023

FSD Pharma Announces Filing of Year-End 2022 Results

TORONTO--(BUSINESS WIRE)--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the filing of its Annual Report on Form 20-F for the year ended December 31, 2022, audited financial results for the fourth quarter and full year then ended and accompanying

Friday, March 31, 2023

IMV Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (“IMV” or the “Company”) (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies based on its novel DPX® platform to treat solid and hematologic cancers, today announced that on March 29, 2023, IMV Inc. (the “Company”) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) indicating that, based upon the closing bid price of the Company’

Friday, March 31, 2023

Biomind Labs Reaches High Purity and Yield of DMT Through an Optimized Extraction Method for Its New Chemical Entity Triptax™

TORONTO--(BUSINESS WIRE)--Biomind Labs Inc. (“Biomind Labs” or the “Company”) (NEO: BMND) (OTC: BMNDF) (FSE: 3XI), a leading biotech company focused on developing the next generation of pharmaceuticals to treat patients suffering from neurological disorders by targeting the drivers of disease, is pleased to announce that it has successfully completed the optimization of a new extraction method to increase the purity and yield of N,N-dimethyltryptamine (“DMT”). DMT was submitted as a Company’s N

Friday, March 31, 2023

Mednow Achieves Record Q2 2023 Financial Results with Quarterly Revenue of $11.3 Million; 17% Q/Q Revenue Growth and 466% Y/Y Revenue Growth; Adjusted EBITDA Improved 32% Y/Y; and Cash Flow from Operations Improved by 7% Q/Q

TORONTO--(BUSINESS WIRE)--Mednow Inc. (“Mednow'' or the “Company”) (TSXV:MNOW) (OTCQX:MDNWF), Canada’s on-demand virtual pharmacy, is pleased to announce it has released its financial results for the period ending January 31, 2023 (“Q2 2023”). Mednow’s Financial Statements and Management, Discussion & Analysis are available on sedar.com and on the Company’s website, https://investors.mednow.ca. Key Milestones, M&A and Partnerships During and Subsequent to Q2 2023: Significant revenue gr

Thursday, March 30, 2023

Devonian Announces Approval of Amendments to its Stock Option Plan and its Restricted Share Unit Plan

QUEBEC CITY--(BUSINESS WIRE)--Devonian Health Group Inc. (“Devonian” or the “Corporation”) (TSXV: GSD; OTCQB: DVHGF), a clinical stage botanical pharmaceutical corporation, focused on developing a unique portfolio of botanical pharmaceutical and cosmeceutical products, is pleased to announce that at the annual and special meeting of its shareholders on March 17, 2023 (the “Meeting”), shareholders approved the renewal of the Corporation stock option plan (the “Option Plan”), as amended, and the

Thursday, March 30, 2023

FSD Pharma Adds Former Celsius Holdings CEO Gerry David to Board of Advisors

TORONTO--(BUSINESS WIRE)---- $HUGE #FSDPharma--FSD Pharma Inc. (NASDAQ: HUGE) (CSE: HUGE) (FRA: 0K9A) (“FSD Pharma” or the “Company”), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative, inflammatory and metabolic disorders, today announced the appointment of Gerry David to the FSD Pharma Advisory Board. Mr. David is best known for his five-year tenure as Chief Executive Officer at zero-calorie fitness drink mak

Thursday, March 30, 2023

ImmunoPrecise’s Subsidiary Talem Enters into Exclusive Research Collaboration and License Option Agreement with Astellas

VICTORIA, British Columbia--(BUSINESS WIRE)---- $IPA #AI--ImmunoPrecise Antibodies Ltd. (NASDAQ: IPA) (“ImmunoPrecise” or “IPA” or the “Company”) an AI-driven biotherapeutic research and technology company today announced a research collaboration and exclusive option license agreement with Xyphos Biosciences, Inc. (a wholly owned subsidiary of Astellas Pharma Inc., “Astellas”). Under the terms of the agreement, the companies will jointly conduct research activities to identify and optimize proprietary LENSa

Thursday, March 30, 2023

NeuPath Health Delivers Record Quarterly Revenues and Opens New Fluoroscopy Suite to Patients

TORONTO--(BUSINESS WIRE)--NeuPath Health Inc. (TSXV:NPTH), (“NeuPath” or the “Company”), owner and operator of a network of clinics delivering category-leading chronic pain treatment, today announced its financial and operating results for the three months and year ended December 31, 2022. All figures are in Canadian dollars, unless otherwise noted. Financial and Operational Highlights Delivered record quarterly total revenue of $16.1 million for the three months ended December 31, 2022 compare

Thursday, March 30, 2023

Gandeeva and Moderna Enter into Cryo-EM Research Collaboration to Explore Protein Surface Structure at Atomic Resolution

VANCOUVER, British Columbia--(BUSINESS WIRE)--Gandeeva Therapeutics, Inc., a precision medicine company focused on designing and developing novel therapeutics guided by cryogenic electron microscopy (cryo-EM) and machine learning, announced today the initiation of a research collaboration with Moderna Inc. (NASDAQ: MRNA) to explore applications of Gandeeva’s differentiated technology platform for a Moderna program. “We are excited to begin working with Moderna on a specific application of our A

Wednesday, March 29, 2023

Biotech and Healthcare Skills Funding Welcomed In Budget 2023

OTTAWA, Ontario--(BUSINESS WIRE)-- #HR--BioTalent Canada applauds the renewed commitment and investments made to skills in the country’s biotech and healthcare sectors in Budget 2023. The $197.7 million in the budget that has been allocated to Canada’s Student Work Placement Program (SWPP) in fiscal year 2024-25 will help particularly to stem a shortfall of 65,000 workers that are needed to sustain this country’s biotechnology and healthcare sectors. While the successful federal program has not been

Tuesday, March 28, 2023

Avivagen Inc. Provides Update on Securities for Service Agreements With CEO and CSO

OTTAWA, Ontario--(BUSINESS WIRE)--Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Company”), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance and support immune function, thereby supporting general health and performance, announces that pursuant to its previously announced “Securities for Services” agreements with Top Meadow Consulting Services Inc. and Mr. Graham Burton, the Company has issued

Tuesday, March 28, 2023

Kontrol Technologies to Report Fiscal Year End 2022 Financial Results

TORONTO--(BUSINESS WIRE)--Kontrol Technologies Corp. (NEO:KNR) (OTCQB:KNRLF) (FSE:1K8) ("Kontrol Technologies" or “Kontrol” or "Company") a leader in smart buildings and cities through IoT, Cloud and SaaS technology will report its Fiscal Year End 2022 financial results, for the period ended December 31st, 2022, on March 31st, 2023 (the “filing date”). A complete set of the Financial Statements and Management's Discussion & Analysis will also be filed on SEDAR (www.sedar.com) on the filing

Tuesday, March 28, 2023

ZYUS Announces Concurrent Private Placement of Subscription Receipts in Connection With Previously Announced RTO

TORONTO--(BUSINESS WIRE)--In connection with its Reverse Takeover Transaction (the “Proposed Transaction”) with Phoenix Canada Oil Company Limited (TSXV: PCO) (“Phoenix”), as originally announced on May 30, 2022, ZYUS Life Sciences Inc. (“ZYUS” or the “Company”) is pleased to announce its intention to complete a concurrent brokered private placement offering of subscription receipts for gross proceeds of C$20,000,000 or such greater amount as agreed to between the Company and the Agents, which

Tuesday, March 28, 2023

AmbioPharm To Utilize YMC Twin-Column Chromatography in Large Scale Peptide Production

NORTH AUGUSTA, S.C. and DEVENS, Mass.--(BUSINESS WIRE)-- #DownstreamProcessing--AmbioPharm, a worldwide leader in peptide API CDMO services, announces the acquisition of new, disruptive, peptide purification technology developed by YMC which leverages several of YMC’s patented1 twin-column purification processes. Twin-column chromatography or Multicolumn Countercurrent Solvent Gradient Purification (MCSGP) is a continuous chromatographic process which collects a high purity center cut fraction and internally recycles

Monday, March 27, 2023

IMV Inc. Announces Changes to Its Board of Directors

DARTMOUTH, Nova Scotia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $IMV #CancerVaccine--IMV Inc. (NASDAQ: IMV; TSX: IMV), a clinical-stage company developing a portfolio of immune-educating therapies, based on its novel DPX platform, to treat solid and hematologic cancers, today announced changes to its board of directors as Shermaine Tilley, Ph.D., MBA has resigned from the Board of Directors ("Board") of the Company, effective immediately. Dr. Tilley, Managing Partner at CTI Life Sciences Fund (“CTI LSF”), was originall

Monday, March 27, 2023

European Patent Office to Grant BioKey’s Patent Application for Foundational HYFT® Technology

VICTORIA, British Colombia--(BUSINESS WIRE)---- $IPA #AI--Immunoprecise Antibodies Ltd. (NASDAQ: IPA) (“Immunoprecise” or “IPA” or the “Company”), the parent company of BioKey and affiliate of BioStrand, announced today that the EPO has issued a “Decision to Grant” for BioKey’s patent application covering the company’s HYFT® Technology used to organize and analyze biological sequence information. The HYFT Technology and methodology provide a novel way to efficiently tap into sequence information, allowing t